In a filing, Moderna Inc revealed its Chief Executive Officer Bancel Stephane acquired Company’s shares for reported $5.0 million on Mar 03 ’25. In the deal valued at $31.22 per share,160,314 shares were bought. As a result of this transaction, Bancel Stephane now holds 9,210,686 shares worth roughly $279.73 million.
Then, SAGAN PAUL bought 31,620 shares, generating $1,004,251 in total proceeds. Upon buying the shares at $31.76, the Director now owns 312,027 shares.
Before that, Klinger Shannon Thyme sold 529 shares. Moderna Inc shares valued at $23,637 were divested by the Chief Legal Officer at a price of $44.68 per share. As a result of the transaction, Klinger Shannon Thyme now holds 20,446 shares, worth roughly $0.62 million.
Barclays downgraded its Moderna Inc [MRNA] rating to an Equal weight from a an Overweight in a research note published on February 18, 2025; the price target was decreased to $45 from $111. A number of analysts have revised their coverage, including Goldman’s analysts, who decreased its forecast for the stock in late January from “a Buy” to “a Neutral”. Argus also remained covering MRNA and has decreased its forecast on December 18, 2024 with a “Hold” recommendation from previously “Buy” rating.
Price Performance Review of MRNA
On Tuesday, Moderna Inc [NASDAQ:MRNA] saw its stock jump 0.33% to $30.37. Over the last five days, the stock has lost -8.74%. Moderna Inc shares have fallen nearly -26.96% since the year began. Nevertheless, the stocks have fallen -67.08% over the past one year. While a 52-week high of $170.47 was reached on 01/07/25, a 52-week low of $29.25 was recorded on 02/14/25. SMA at 50 days reached $37.02, while 200 days put it at $74.28.
Levels Of Support And Resistance For MRNA Stock
The 24-hour chart illustrates a support level at 29.43, which if violated will result in even more drops to 28.49. On the upside, there is a resistance level at 31.23. A further resistance level may holdings at 32.08. The Relative Strength Index (RSI) on the 14-day chart is 37.77, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -2.31, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 85.51%. Stochastics %K at 16.60% indicates the stock is a buying.
The most recent change occurred on November 19, 2024 when Berenberg began covering the stock and recommended ‘”a Hold”‘ rating along with a $42 price target.
